Archive — CN — technode
Genlight Medical raises several hundred million yuan in C and D rounds
Genlight Medical has successfully raised several hundred million yuan in C and D financing rounds, led by Qiming Venture Partners and backed by various investors, to advance its Epilcure neurostimulation system and Vivastep spinal interface aimed at treating drug-resistant focal epilepsy.
Key points
- Genlight Medical completed C and D financing rounds.
- C round was led by Qiming Venture Partners.
- D round involved investors including Saizhi Bole and Kuanqiao Hengsong.
- Funds will be used for advancing Epilcure neurostimulation system registration.
- Vivastep spinal interface will undergo clinical translation and regulatory filings.
Why it matters
- Investment in neurostimulation technology aligns with increasing focus on digital healthcare solutions.
- 2025 IT trends indicate a surge in the use of AI and tech for healthcare innovations.
- Funding for medical startups has risen significantly due to the COVID-19 pandemic's emphasis on healthcare advancements.
The successful funding rounds signify growing confidence in innovative medical technologies, asserting Genlight Medical's potential impact on the treatment of challenging neurological conditions.